Brief: European Commission Approves Celltrion Healthcare's Vegzelma For The Treatment Of Multiple Types Of Cancer
Aug 18 (Reuters) - Celltrion Healthcare Co Ltd 091990.KQ :
* EUROPEAN COMMISSION APPROVES CELLTRION HEALTHCARE'S
VEGZELMA™
(CT-P16, BIOSIMILAR BEVACIZUMAB) FOR THE TREATMENT OF MULTIPLE
TYPES OF CANCER
Source text for Eikon: ID:nBw95gQ56a
Further company coverage: 091990.KQ
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap